Theravance Biopharma IncTBPH
Price$17.03Intrinsic value$9.8742% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $104.3M+62.0% YoYTTM through 30 Jun 2026
Net Income $53.8MTTM through 30 Jun 2026
Free Cash Flow $53.7MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin0.1%
Operating Margin-53.6%
Net Margin51.6%

Returns

26.0%ROE
24.3%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio12.89x
Net Debt-$393.9Mnet cash position
Cash & Equivalents$219.8M

Quality Metrics

Altman Z-Score1.53
Piotroski F-Score5 / 9
FCF Margin51.5%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $107.5M
Diluted EPS$1.01TTM
'19'20'21'22'23'24'25
FY2025: $2.06

Dividend

No dividend

Capital Allocation

R&D Spend$26M
Capex Intensity0.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.